Biopharma M&A Activity Surges as Patent Cliff Drives Deal-Making
The biopharmaceutical sector has seen robust recovery in Q1 2026, with US pharma and life sciences deal value surpassing $65 billion—the highest since the pandemic peak of 2020. This surge is driven by a patent cliff that threatens billions in branded revenue, prompting companies to pursue mergers and acquisitions for pipeline diversification.
Tickers: $LLY
Topics: biopharmaceuticals mergers and acquisitions patent cliff R&D strategy